Study unit 3.1
What are the therapeutic effects of theophylline in the treatment of bronchial asthma?
Beta-adrenoceptor agonists stimulate adenylyl cyclase (via the β2-adrenoceptor–Gs-coupling protein-adenylyl cyclase pathway) and increase cyclic adenosine monophosphate (cAMP) in smooth muscle cells . The increase in cAMP results in a powerful bronchodilator response.
Primary mechanisms: Bronchodilation and smooth muscle relaxation
Mechanism Of Action of B-2 agonists: stimulate adenyl cyclase which causes cAMP to increase in bronchial smooth muscle which thereafter causes bronchodilation
Molecular pharmacology: Bronchodilation and Vasodilation of smooth muscle (SM) vessels are effects of B2 agonist stimulation. At high doses also B1 stimulating effects which cause possible side effects such as tachycardia.
• Stimulant, increased alertness, insomnia, high doses: CENTRAL NERVOUS SYSTEM
• Elevated ino- and chronotropy: CVS
• Increased gastric acid and digestive enzyme secretion: GASTRO INTESTINAL TRACT
• Increased glomerular filtration rate, diuresis (Renal): KIDNEYS
• Strengthens contraction of diaphragm: SKELETAL MUSCLE
Theophylline has a very narrow therapeutic window, patients are at an increased risk of serious theophylline toxicity. Since nearly all of theophylline dose is biotransformed, drugs influencing microsomal enzyme systems in the liver may affect the elimination of theophylline. Other integrated mechanisms (e.g. hepatic uptake) may also be altered by concurrent administration of other drugs. Whatever the mechanism, the interaction may be sufficient to necessitate adjustment of the theophylline dosage, preferably guided by plasma theophylline determinations. Many drugs have been found to increase or decrease the clearance of theophylline, by interaction with one or more of the variants of the cytochrome P450 drug-metabolising system. Theophylline is susceptible to alteration of its clearance because of the particular forms of the P450 system involved, because its metabolism is saturable, and/or because 90% of its elimination is via metabolism. Drug examples include:
By aerosol, these drugs competitively block muscarinic receptors in the airways and effectively prevent bronchoconstriction mediated by vagal discharge. If given systemically (not an approved use), these drugs are indistinguishable from other short-acting muscarinic blockers. Because these agents are delivered directly to the airway and are minimally absorbed, systemic effects are small. When given in excessive dosage, minor atropine-like toxic effects may occur.